✦ LIBER ✦

Interpreting breast international group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer

✍ Scribed by Meredith M Regan; Karen N Price; Anita Giobbie-Hurder; Beat Thürlimann; Richard D Gelber; for the International Breast Cancer Study Group and BIG 1-98 Collaborative Group

Book ID: 118726736
Publisher: BioMed Central
Year: 2011
Tongue: English
Weight: 368 KB
Volume: 13
Category: Article
ISSN: 1465-5411
DOI: 10.1186/bcr2837

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Design, conduct, and analyses of Breast

Design, conduct, and analyses of Breast International Group (BIG) 1-98: A randomized, double-blind, phase-III study comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancer

✍ Giobbie-Hurder, A.; Price, K. N; Gelber, R. D 📂 Article 📅 2009 🏛 SAGE Publications 🌐 English ⚖ 194 KB

S4 Letrozole vs. Tamoxifen as adjuvant e

S4 Letrozole vs. Tamoxifen as adjuvant endocrine therapy for postmenopausal women in receptor-positive breast cancer. BIG 1-98: A prospective randomized double-blind phase III study

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 73 KB

First results of a randomized phase III

First results of a randomized phase III trial comparing exemestane versus tamoxifen as first-line hormone therapy (HT) for postmenopausal women with metastatic breast cancer (MBC) — EORTC 10951 in collaboration with the exemestane working group and NCIC Clinical Trials Group

✍ R Paridaens; P Therasse; L Dirix; L Beex; M.J Piccart; D Cameron; T Cufer; K Roo 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 172 KB